Citations

Showing 10 of 108083 citations.

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
Abramson, Jeremy S. , Solomon, Scott R. , Arnason, Jon , Johnston, Patrick B. , Glaß, Bertram , Bachanová, Veronika , Ibrahimi, Sami , Mielke, Stephan , Mutsaers, Pim , Hernandez‐Ilizaliturri, Francisco J. , Lunning, Matthew A. , Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro , Novak, Urban , Morschhauser, Franck , Ogasawara, Ken , Bachanova, Veronika , Abramson, Jeremy S , Mielke, Stephan , Ibrahimi, Sami , Izutsu, Koji , Morschhauser, Franck , Kamdar, Manali

Mayo Clinic

Blood | December 21, 2022 | Volume: 141 | Issue: 14 | Pages: 1675-1684

10.1182/blood.2022018730 | PMID 36542826 Get It

Abstract This global phase 3 study compared lisocabtagene maraleucel (liso-cel) with a standard of care (SOC) as second-line therapy for primary refractory or early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (ASCT; N = 184) were randomly assigned in a 1:1 ratio to liso-cel (100 × 106 chimeric antigen receptor–positive T cells) or SOC (3 cycles of platinum-based immunochemotherapy followed by high-dose chemotherapy and ASCT in responders). The primary end point was event-free survival (EFS). In this primary analysis with a 17.5-month median follow-up, median EFS was not reached (NR) for liso-cel vs 2.4 months for SOC. Complete response (CR) rate was 74% for liso-cel vs 43% for SOC (P < .0001) and median progression-free survival (PFS) was NR for liso-cel vs 6.2 months for SOC (hazard ratio [HR] = 0.400; P < .0001). Median overall survival (OS) was NR for liso-cel vs 29.9 months for SOC (HR = 0.724; P = .0987). When adjusted for crossover from SOC to liso-cel, 18-month OS rates were 73% for liso-cel and 54% for SOC (HR = 0.415). Grade 3 cytokine release syndrome and neurological events occurred in 1% and 4% of patients in the liso-cel arm, respectively (no grade 4 or 5 events). These data show significant improvements in EFS, CR rate, and PFS for liso-cel compared with SOC and support liso-cel as a preferred second-line treatment compared with SOC in patients with primary refractory or early relapsed LBCL. This trial was registered at www.clinicaltrials.gov as #NCT03575351.
Focused Empiricism and the Efficacy of Resuscitative Endovascular Balloon Occlusion of the Aorta
Rasmussen, Todd E.

Mayo Clinic

JAMA Surgery | December 21, 2022 | Volume: 158 | Issue: 2 | Pages: 150

10.1001/jamasurg.2022.6430 | PMID 36542387 Get It

Explainable AI for ECG-based prediction of cardiac resynchronization therapy outcomes: learning from machine learning?
Attia, Zachi I. , Friedman, Paul A. , Attia, Zachi I

Mayo Clinic

European Heart Journal | December 21, 2022 | Volume: 44 | Issue: 8 | Pages: 693-695

10.1093/eurheartj/ehac733 | PMID 36546617 Get It

Cardiac amyloidosis remains significantly underdiagnosed in patients undergoing TAVR: analysis of National Inpatient Sample
Panagiotopoulos, Ιoannis , Tsioufis, Konstantinos , Elgendy, Islam Y. , Elgendy, Islam Y , Panagiotopoulos, Ioannis , Terentes-Printzios, Dimitrios G. , Antonopoulos, Alexios S. , Omer, Mohamed , Toutouzas, Konstantinos G. , Vlachopoulos, Charalambos V.

Mayo Clinic

Amyloid | December 21, 2022 | Volume: 30 | Issue: 2 | Pages: 246-247

10.1080/13506129.2022.2159369 | PMID 36541785 Get It

Feasibility and Efficacy of a Non-Opioid Based Pain Management After Medical Thoracoscopy
Low, See‐Wei , Mullon, John J., Swanson, Karen L., Kern, Ryan , Nelson, Darlene R. , Fernández-Bussy, Sebastián , Sakata, Kenneth K. , Kern, Ryan M, Kern, R

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | December 21, 2022 | Volume: 30 | Issue: 4 | Pages: 321-327

10.1097/lbr.0000000000000908 | PMID 36541719 Get It

Background: Prescription opioids are a major cause of the opioid epidemic. Despite the minimally invasive nature of medical thoracoscopy (MT), data on the efficacy of non-opioid-based pain control after MT is lacking. The purpose of this study is to assess the feasibility and efficacy of a non-opioid-based pain management strategy in patients who underwent MT. Methods: We performed a retrospective analysis of all patients who underwent MT in the Mayo Clinic (Minnesota and Arizona) outpatient setting. We assessed their pain level and the need for analgesia post-MT from August 1, 2019, to May 24, 2021. Results: Forty patients were included. In the first 24 hours, 5/40 (12.5%) reported no pain. Twenty-eight patients out of 40 (70%) reported minor pain (pain scale 1-3), and 7/40 (17.5%) reported moderate pain (pain scale 4-6). No patients reported severe pain. Twenty-two out of 35 patients who experienced discomfort (63%) required acetaminophen, 6/35 patients (17%) required nonsteroidal anti-inflammatory drug, and 7/35 patients (20%) did not require analgesia. Of the 7 patients who had moderate pain, 5 (71%) reported that the moderate pain improved to mild at 72 hours post-MT. Zero patients required opioids, and none reported contacting any provider to manage the pain post-MT. Fourteen patients (78%) who had both parietal pleural biopsies and tunneled pleural catheter placed reported minor pain, 3 patients (17%) reported moderate pain, and 1 patient (6%) experienced no discomfort. Conclusion: MT is well-tolerated by patients with non-opioid-based pain management strategy as needed if there is no absolute contraindication.
Intracellular NO Delivery by Si-Based Ni Composite Nanoflowers
Lee, Do Nam , Gwon, Kihak , Yu, Jeong‐Hoon , Kim, Yeong Rim, Lee, Su Jung , Shin, Jae Ho , Yu, Jong‐Sung , Gwon, Kihak , Park, Gisang , Han, Ihn

Mayo Clinic

ACS Applied Nano Materials | December 21, 2022 | Volume: 6 | Issue: 2 | Pages: 846-855

10.1021/acsanm.2c03960 Get It

New features of parenteral nutrition in home care and acute care setting for the older population
Salonen, Bradley R. , Salonen, Bradley, Martindale, Robert G.

Mayo Clinic

Current Opinion in Clinical Nutrition & Metabolic Care | December 21, 2022 | Volume: 26 | Issue: 1 | Pages: 32-35

10.1097/mco.0000000000000887 | PMID 36542533 Get It

Purpose of review The intent of this review is to highlight any recent changes in the delivery of parenteral nutrition to the geriatric population. The percentage of patients in the geriatric age group increases clinical awareness of the potential risks and benefits of appropriate parenteral nutrition delivery, which is crucial to well tolerated and optimum outcomes. Recent findings The major recent finding is the increased awareness of risk of parenteral nutrition in the elderly population. Summary The implications of this very brief review expose the need for further focused studies to better clarify the specifics of parenteral nutrition in this vulnerable ageing population. The importance of nutritional risk assessment cannot be overstated. With the rapidly expanding volume of geriatric population, the need for more data to better understand the delicate balance in parenteral nutrition therapy for both the acute care setting and home parenteral population is needed.
Post-Surgical Strategies for Prostate Cancer: Clinicopathologic and Genomics Criteria
Morlacco, Alessandro , Soligo, Matteo, Colicchia, Michele , Nehra, Avinash , Karnes, R. Jeffrey

Mayo Clinic

EMJ Oncology | December 21, 2022 | Volume: No volume available | Issue: No issue available | Pages: 70-77

10.33590/emjoncol/10311368 Get It

Radical prostatectomy is widely used as the primary modality of treatment for clinically localised prostate cancer. A considerable proportion of men will have adverse histopathologic features and could benefit from adjunctive treatments: mainly adjuvant or salvage radiation. This review focusses on the still unanswered questions: How to manage the patient after radical prostatectomy? Which patients need further treatment and which ones will not progress if not treated? How to refine patients selection for further treatments? What is the role for clinical nomograms and biomarkers and which ones are validated? When is it wise to propose adjuvant radiation therapy (RT) instead of observation with or without salvage RT? What is the optimal timing for the use of salvage RT and how to choose patients for each approach? This article discusses the evidence available in the current literature, providing a critical analysis of the controversies of each strategy.
Publication Ethics and Misconducts
Khanna, Sahil , Sachan, Anurag , Sharma, Vishal

Mayo Clinic

Indian Journal of Rheumatology | December 21, 2022 | Volume: 17 | Issue: 2S | Pages: No page available

10.4103/0973-3698.364678 Get It

Chronic Skin Picking: Trigeminal Trophic Syndrome in the Setting of Meningioma
Trischman, Thomas , Demer, Addison M. , Vidal, Nahid Y.

Mayo Clinic

Dermatologic Surgery | December 21, 2022 | Volume: 49 | Issue: 2 | Pages: 206-208

10.1097/dss.0000000000003678 | PMID 36541872 Get It